Study the Effects of CYP2C Polymorphisms on the Pharmacokinetics and Pharmacodynamics of Glipizide

Summary

The aims of this study were to investigate the effects of CYP2C9 and CYP2C19 polymorphisms on the pharmacokinetics and pharmacodynamics of glipizide in healthy Chinese subjects.

Description

Compared with CYP2C19, CYP2C9 polymorphism appears to have a dominant role in glipizide pharmacokinetics and pharmacodynamics in vivo. This indicated that dose adjustment based on CYP2C9 genotype may improve antidiabetic treatment.

Study Design

Observational Model: Case Control, Time Perspective: Prospective

Conditions

Healthy

Location

The second hospital to Liaoning University of TCM
Shenyang
Liaoning
China
201203

Status

Completed

Source

Chinese Academy of Sciences

Results (where available)

View Results

Links

• Source: http://clinicaltrials.gov/show/NCT00806013
• Information obtained from ClinicalTrials.gov on July 15, 2010

More From BioPortfolio on "Study the Effects of CYP2C Polymorphisms on the Pharmacokinetics and Pharmacodynamics of Glipizide"

• Related Companies
• Related Events
• Related Clinical Trials
• Related PubMed Entries
• Related Medications